Blepharitis Stocks List
Symbol | Grade | Name | % Change | |
---|---|---|---|---|
TARS | D | Tarsus Pharmaceuticals, Inc. | 5.01 | |
KALA | D | Kala Pharmaceuticals, Inc. | 1.64 |
Related Industries: Biotechnology
Symbol | Grade | Name | Weight | |
---|---|---|---|---|
XPH | D | SPDR S&P Pharmaceuticals ETF | 1.85 | |
PILL | F | Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF | 1.4 | |
BBP | C | BioShares Biotechnology Products Fund | 1.21 | |
SBIO | D | ALPS Medical Breakthroughs ETF | 0.72 | |
IHE | B | iShares U.S. Pharmaceutical ETF | 0.31 |
Compare ETFs
Date | Stock | Title |
---|---|---|
Jun 27 | KALA | Kala Pharmaceuticals to sell 1.197M shares at $5.85 in private placement |
Jun 27 | KALA | KALA BIO Announces $12,500,000 Private Placement |
- Blepharitis
Blepharitis is one of the most common ocular conditions characterized by inflammation, scaling, reddening, and crusting of the eyelid. This condition may also cause burning, itching, or a grainy sensation when introducing foreign objects or substances to the eye. Although blepharitis is not sight-threatening, it can lead to permanent alterations of the eyelid margin. The overall etiology is a result of bacteria and inflammation from congested meibomian oil glands at the base of each eyelash. Other conditions may give rise to blepharitis, whether they be infectious or noninfectious, including, but not limited to, bacterial infections or allergies.
Different variations of blepharitis can be classified as seborrheic, staphylococcal, mixed, posterior or meibomitis, or parasitic. In a survey of US ophthalmologists and optometrists, 37% to 47% of patients seen by those surveyed had signs of blepharitis, which can affect all ages and ethnic groups. One single-center study of 90 patients with chronic blepharitis found that the average age of patients was 50 years old.
Recent Comments
- TraderMike on Bollinger Band Squeeze
- TraderMike on Bollinger Band Squeeze
- OpenCat584 on Bollinger Band Squeeze
- Dr_Duru on Expansion Breakout
- TraderMike on New Scans: Strong, Oversold Stocks and Weak, Overbought Stocks
From the Blog
Featured Articles